Ashley Woodcock
Overview
Explore the profile of Ashley Woodcock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
139
Citations
3204
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Wilkinson T, Soyza A, Carroll M, Chalmers J, Crooks M, Griffiths G, et al.
ERJ Open Res
. 2023 Oct;
9(5).
PMID: 37868151
Background: Increased serum interleukin (IL)-33 predicts poor outcomes in patients hospitalised with coronavirus disease 2019 (COVID-19). We examined the efficacy and safety of tozorakimab, a monoclonal antibody that neutralises IL-33,...
3.
4.
5.
Zeng X, Qing J, Li C, Lu J, Yamawaki T, Hsu Y, et al.
J Allergy Clin Immunol
. 2023 Jun;
152(4):876-886.
PMID: 37315813
Background: Patients with type-2 (T2) cytokine-low severe asthma often have persistent symptoms despite suppression of T2 inflammation with corticosteroids. Objectives: We sought to analyze whole blood transcriptome from 738 samples...
6.
Turner S, Khan M, Putrino D, Woodcock A, Kell D, Pretorius E
Trends Endocrinol Metab
. 2023 Apr;
34(6):321-344.
PMID: 37080828
Acute COVID-19 infection is followed by prolonged symptoms in approximately one in ten cases: known as Long COVID. The disease affects ~65 million individuals worldwide. Many pathophysiological processes appear to...
7.
DeNucci G, Wilkinson T, Sverdloff C, Babadopulos T, Woodcock A, Shute J, et al.
Pulm Pharmacol Ther
. 2023 Mar;
80:102212.
PMID: 36990381
There is a strong scientific rationale to use nebulised unfractionated heparin (UFH) in treating patients with COVID-19. This pilot study investigated whether nebulised UFH was safe and had any impact...
8.
Eastwood M, Busby J, Jackson D, Pavord I, Hanratty C, Djukanovic R, et al.
J Allergy Clin Immunol Pract
. 2023 Jan;
11(4):1233-1242.e5.
PMID: 36621603
Background: Approximately 5% to 10% of patients with asthma have severe disease, with a consistent preponderance in females. Current asthma guidelines recommend stepwise treatment to achieve symptom control with no...
9.
McDowell P, Busby J, Hanratty C, Djukanovic R, Woodcock A, Walker S, et al.
Am J Respir Crit Care Med
. 2022 May;
206(5):545-553.
PMID: 35549845
The past 25 years have seen huge progress in understanding of the pathobiology of type-2 (T2) asthma, identification of measurable biomarkers, and the emergence of novel monoclonal antibody treatments. Although...
10.
Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD
Vestbo J, Waterer G, Leather D, Crim C, Bakerly N, Frith L, et al.
Eur Respir J
. 2022 Mar;
59(5).
PMID: 35273031
No abstract available.